Einloggen

Thematische Bibliographien / Fibrosis / Zeitschriftenartikel

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Fibrosis.

Zeitschriftenartikel zum Thema „Fibrosis“

Autor: Grafiati

Veröffentlicht am 4. Juni 2021

Zuletzt aktualisiert am 25. Juli 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Fibrosis" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

&NA;. "Cystic fibrosis and fibrosing colonopathy." Advances in Anatomic Pathology 3, no. 2 (1996): 112. http://dx.doi.org/10.1097/00125480-199603000-00015.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Smyth, R. L. "Fibrosing colonopathy in cystic fibrosis." Archives of Disease in Childhood 74, no. 5 (1996): 464–68. http://dx.doi.org/10.1136/adc.74.5.464.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Egea-Zorrilla, Alejandro, Zuri馿 Blasco-Iturri, Borja Saez, and Ana Pardo-Saganta. "The Notch3 Pathway in Organ Fibrosis." Fibrosis 2, no. 4 (2024): 10007. http://dx.doi.org/10.70322/fibrosis.2024.10007.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Moreno Diaz, Claudia, Estrella Caballeria, and Jacobo Sellar閟 Torres. "Comparative Analysis of Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis: Epidemiology, Pathophysiology, Clinical Features, Diagnosis and Treatment." Fibrosis 3, no. 1 (2025): 10001. https://doi.org/10.70322/fibrosis.2025.10001.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Carrino, David A., Sam Mesiano, Nichole M. Barker, William W. Hurd, and Arnold I. Caplan. "Proteoglycans of uterine fibroids and keloid scars: similarity in their proteoglycan composition." Biochemical Journal 443, no. 2 (2012): 361–68. http://dx.doi.org/10.1042/bj20111996.

Der volle Inhalt der Quelle

Annotation:

Fibrosis is the formation of excess and abnormal fibrous connective tissue as a result of either a reparative or reactive process. A defining feature of connective tissue is its extracellular matrix, which provides structural support and also influences cellular activity. Two common human conditions that result from fibrosis are uterine fibroids (leiomyomas) and keloid scars. Because these conditions share a number of similarities and because their growth is due primarily to excessive extracellular matrix deposition, we compared the proteoglycans of uterine fibroids and keloid scars with corre

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Khan, Khaleque N., Akira Fujishita, Akemi Koshiba, et al. "Expression profiles of E/P receptors and fibrosis in GnRHa-treated and -untreated women with different uterine leiomyomas." PLOS ONE 15, no. 11 (2020): e0242246. http://dx.doi.org/10.1371/journal.pone.0242246.

Der volle Inhalt der Quelle

Annotation:

Differential expressions of estrogen/progesterone receptors (ER/PR) and individual component of extracellular matrices derived from fibroid are reported. Information on the pattern of change in ER/PR expression and amount of tissue fibrosis after hormonal treatment is unclear. We investigated pattern of change in ER/PR expression and percentage of tissue fibrosis in different uterine leiomyomas after gonadotropin-releasing hormone agonist (GnRHa) treatment. Biopsy specimens from fibroids and adjacent myometria were collected after surgery from women with submucosal myoma (SMM, n = 18), intramu

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Sferrazza, Sandro, Marcello Maida, Giulio Calabrese, et al. "The Derivation and External Validation of a Fibrosis Risk Model for Colorectal Tumours Undergoing Endoscopic Submucosal Dissection." Journal of Clinical Medicine 13, no. 15 (2024): 4517. http://dx.doi.org/10.3390/jcm13154517.

Der volle Inhalt der Quelle

Annotation:

Background: Endoscopic submucosal dissection (ESD) is an advanced technique that can become more challenging in the presence of submucosal fibrosis. Predicting the grade of fibrosis is important in order to identify technically difficult ESD. Aims and Methods: Our study aimed to derive and validate a prediction model to determine the preoperative degree of submucosal fibrosis in colorectal tumours undergoing ESD. A predictive model was developed to derive the probability of an increasing submucosal fibrosis in the derivation cohort and then externally validated. Results: 309 patients (age: 68

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Pintér, István, Katalin Vágási, István Wittmann, and Judit Nagy. "Nephrogenic systemic fibrosis." Orvosi Hetilap 148, no. 38 (2007): 1801–4. http://dx.doi.org/10.1556/oh.2007.28183.

Der volle Inhalt der Quelle

Annotation:

A nefrogén szisztémás fibrosis, melyet korábban nefrogén fibrotizáló dermopathiaként említett az irodalom, egy ritka kórkép, mely vesebetegeknél jelentkezik. A kialakulását elsősorban gadolínium alapú MRI-kontrasztanyag alkalmazását követően észlelték beszűkült vesefunkciójú, többnyire dializált betegeken. A nefrogén szisztémás fibrosist a végtagok distalis részén kezdődő, majd a súlyosabb esetekben a tüdőt, májat, szív- és vázizomzatot is érintő fibrosis jellemzi. A betegség több szervrendszer együttes érintettsége esetén – az esetek mintegy 5%-ában – gyors lefolyású és halálos kimenetelű is

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Samokhodskaia, Larisa Mikhaylovna, Ekaterina Evgen'evna Starostina, Elena Borisovna Yarovaya, et al. "Mathematic Model for Prediction of Liver Fibrosis Progression Rate in Patients with Chronic Hepatitis C Based on Combination of Genomic Markers." Annals of the Russian academy of medical sciences 70, no. 6 (2015): 651–61. http://dx.doi.org/10.15690/vramn548.

Der volle Inhalt der Quelle

Annotation:

Aim of study. To evaluate clinical significance of different combinations of gene polymorphisms IL-1b, IL-6, IL-10, TNF, HFE, TGF-b, ATR1, NOS3894, CYBA, AGT, MTHFR, FII, FV, FVII, FXIII, ITGA2, ITGB3, FBG, PAI and their prognostic value for prediction of liver fibrosis progression rate in patients with chronic hepatitis C (CHC).Subjects and methods: 118 patients with CHC were divided into «fast» and «slow» (fibrosis rate progression ≥0,13 and 0,13 fibrosis units/yr; n =64 and n =54) fibrosis groups. Gene polymorphisms were determined. Statistical analysis was performed using Statistica 10.Res

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Bertero, Michele, Serena Bainotti, Alberto Comino, et al. "Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis." European Journal of Dermatology 19, no. 1 (2009): 073–74. http://dx.doi.org/10.1684/ejd.2008.0547.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

du Bois, R. M., and A. U. Wells. "Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis." European Respiratory Journal 18, no. 32 suppl (2001): 43S—55S. http://dx.doi.org/10.1183/09031936.01.18s320043.

Der volle Inhalt der Quelle

Annotation:

Cryptogenic fibrosing alveolitis (CFA), synonymous with idiopathic pulmonary fibrosis (IPF), remains a life-threatening disease: 50% of patients die within 5 yrs. Historically, many diseases that are now considered to be quite distinct have been “labelled” as CFA. More recently, high-resolution computed tomography and new appreciation of the histopathological patterns of idiopathic interstitial pneumonias have enabled disease variants to be defined according to their different responses to therapy and survival.CFA is believed to be induced by an external agent, although it is not clear whether

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Prasad, Srinivasa R., and Jaishree Jagirdar. "Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing Dermopathy." Journal of Computer Assisted Tomography 32, no. 1 (2008): 1–3. http://dx.doi.org/10.1097/rct.0b013e31805d08ee.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Galan, Anjela, Shawn E. Cowper, and Richard Bucala. "Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy)." Current Opinion in Rheumatology 18, no. 6 (2006): 614–17. http://dx.doi.org/10.1097/01.bor.0000245725.94887.8d.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

Fellrath, J. M., and R. M. du Bois. "Idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis." Clinical and Experimental Medicine 3, no. 2 (2003): 65–83. http://dx.doi.org/10.1007/s10238-003-0010-3.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

Ma, Hongge, Shupei Qiao, Zeli Wang, et al. "Microencapsulation of Lefty-secreting engineered cells for pulmonary fibrosis therapy in mice." American Journal of Physiology-Lung Cellular and Molecular Physiology 312, no. 5 (2017): L741—L747. http://dx.doi.org/10.1152/ajplung.00295.2016.

Der volle Inhalt der Quelle

Annotation:

Idiopathic pulmonary fibrosis (IPF) is a progressive disease that causes unremitting deposition of extracellular matrix proteins, thus resulting in distortion of the pulmonary architecture and impaired gas exchange. Associated with high morbidity and mortality, IPF is generally refractory to current pharmacological therapies. Lefty A, a potent inhibitor of transforming growth factor-β signaling, has been shown to have promising antifibrotic ability in vitro for the treatment of renal fibrosis and other potential organ fibroses. Here, we determined whether Lefty A can attenuate bleomycin (BLM)-

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Huang, Chenyu, and Rei Ogawa. "The Vascular Involvement in Soft Tissue Fibrosis—Lessons Learned from Pathological Scarring." International Journal of Molecular Sciences 21, no. 7 (2020): 2542. http://dx.doi.org/10.3390/ijms21072542.

Der volle Inhalt der Quelle

Annotation:

Soft tissue fibrosis in important organs such as the heart, liver, lung, and kidney is a serious pathological process that is characterized by excessive connective tissue deposition. It is the result of chronic but progressive accumulation of fibroblasts and their production of extracellular matrix components such as collagens. Research on pathological scars, namely, hypertrophic scars and keloids, may provide important clues about the mechanisms that drive soft tissue fibrosis, in particular the vascular involvement. This is because these dermal fibrotic lesions bear all of the fibrotic chara

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Masuzaki, Ryota, Tatsuo Kanda, Reina Sasaki, et al. "Noninvasive Assessment of Liver Fibrosis: Current and Future Clinical and Molecular Perspectives." International Journal of Molecular Sciences 21, no. 14 (2020): 4906. http://dx.doi.org/10.3390/ijms21144906.

Der volle Inhalt der Quelle

Annotation:

Liver fibrosis is one of the risk factors for hepatocellular carcinoma (HCC) development. The staging of liver fibrosis can be evaluated only via a liver biopsy, which is an invasive procedure. Noninvasive methods for the diagnosis of liver fibrosis can be divided into morphological tests such as elastography and serum biochemical tests. Transient elastography is reported to have excellent performance in the diagnosis of liver fibrosis and has been accepted as a useful tool for the prediction of HCC development and other clinical outcomes. Two-dimensional shear wave elastography is a new techn

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

LYON, IAN C. T., and DIANNE R. WEBSTER. "Newborn Screening for Cystic Fibrosis." Pediatrics 87, no. 6 (1991): 954–55. http://dx.doi.org/10.1542/peds.87.6.954.

Der volle Inhalt der Quelle

Annotation:

To the Editor.— The report on newborn screening for cystic fibrosis1 illustrates the need for continued evaluation of such programs. The authors state that the identification of cases of cystic fibrosis (CF) by an elevated level of immunoreactive trypsinogen (IRT) in second (follow-up) samples from infants with positive initial screening tests could result in false negatives in 27% of cases of cystic fibrosis without meconium ileus (MI). We have screened 401 122 infants using the method originally reported.2

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Yu, Guoying. "Fibrosis: A New Open-Access Journal to Share Your Research." Fibrosis 1, no. 1 (2023): 1–2. http://dx.doi.org/10.35534/fibrosis.2023.10001.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

Vijayakumar, Bavithra, and Pallav L. Shah. "Is Fibrosis Really Fibrosis?" American Journal of Respiratory and Critical Care Medicine 203, no. 11 (2021): 1440–42. http://dx.doi.org/10.1164/rccm.202102-0334le.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

D'Amico, A., V. Ficarra, A. Porcaro, et al. "L'eziopatogenesi della fibrosi retroperitoneale: Etiopathogenesis of retroperitoneal fibrosis." Urologia Journal 65, no. 2 (1998): 257–66. http://dx.doi.org/10.1177/039156039806500213.

Der volle Inhalt der Quelle

Annotation:

The etiopathogenesis of retroperitoneal fibrosis is still obscure and probably multifactorial. Among the secondary forms due to demonstrable causes, the one caused by aorto-iliac atherosclerosis has recently been recognised. Its pathogenesis is linked to the low density oxidised lipoproteins of the atheromatous plaque, which are responsible for a local immunologic reaction. The most common form is still idiopathic or primitive, hypothetically related to genetic, environmental, vascular and/or immunologic factors. Idiopathic retroperitoneal fibrosis is sometimes associated with other sclerosing

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

Li, Zhenwei, Zhao Zhu, Jiawei Wang, et al. "Exploring the Potential Relationship between Gut Microbiome Metabolites and Idiopathic Pulmonary Fibrosis via Network Pharmacology Study." Fibrosis 2, no. 4 (2024): 10009. http://dx.doi.org/10.70322/fibrosis.2024.10009.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Wang, Yanrong, Zuhao Li, Chenyang Zhang, Ziqi Jin, and Adam C. Midgley. "Dermal Fibrosis and the Current Scope of Hydrogel Strategies for Scarless Wound Healing." Fibrosis 2, no. 4 (2024): 10010. http://dx.doi.org/10.70322/fibrosis.2024.10010.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Arevalo, Carlo, and David J. Nagel. "Acute Exacerbations of Interstitial Lung Disease: Evolving Perspectives on Diagnosis and Management." Fibrosis 2, no. 4 (2024): 10008. http://dx.doi.org/10.70322/fibrosis.2024.10008.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

R. Lapthorn, Alice, Sophie L. Harding, Kieran M. Feltham, Deepika Sathyananth, Daniel C. Salisbury, and Selim Cellek. "A Review of the Current Landscape of Anti-Fibrotic Medicines." Fibrosis 2, no. 1 (2024): 10005. http://dx.doi.org/10.70322/fibrosis.2024.10005.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Jamalinia, Mohamad, Amedeo Lonardo, and Ralf Weiskirchen. "Sex and Gender Differences in Liver Fibrosis: Pathomechanisms and Clinical Outcomes." Fibrosis 2, no. 1 (2024): 10006. http://dx.doi.org/10.70322/fibrosis.2024.10006.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

Weiskirchen, Ralf, H鍁ard Attramadal, and Bernard Perbal. "12th International Workshop on the CCN Family of Genes." Fibrosis 2, no. 1 (2024): 10003. http://dx.doi.org/10.35534/fibrosis.2024.10003.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Guo, Xiaoshu, Yue Zhang, Yingjie Wang, et al. "Mitochondrial Damage and Epithelial-Mesenchymal Transition as Major Triggers of the Development of Idiopathic Pulmonary Fibrosis." Fibrosis 2, no. 1 (2024): 10004. http://dx.doi.org/10.35534/fibrosis.2024.10004.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

Victorovich Garbuzenko, Dmitry. "Perspectives of Drug Therapy for Non-Alcoholic Steatohepatitis-Related Liver Fibrosis." Fibrosis 3, no. 1 (2025): 10002. https://doi.org/10.70322/fibrosis.2025.10002.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

Tsomidis, Ioannis, George Notas, Argyro Voumvouraki, Dimitrios Samonakis, Mairi Koulentaki, and Elias Kouroumalis. "Hepatic Lysosomal Enzyme Activity in Primary Biliary Cholangitis." Fibrosis 1, no. 1 (2023): 1–12. http://dx.doi.org/10.35534/fibrosis.2023.10005.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Li, Zhongzheng, Huabin Zhao, Shenghui Wang, et al. "Comprehensive Landscape of Matrix Metalloproteinases in the Pathogenesis of Idiopathic Pulmonary Fibrosis." Fibrosis 1, no. 1 (2023): 1–14. http://dx.doi.org/10.35534/fibrosis.2023.10004.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

David, Elroei, Alina Karabchevsky, Marina Wolfson, and Vadim E. Fraifeld. "Pulsed Ultraviolet C as a Potential Treatment for COVID-19." Fibrosis 1, no. 1 (2023): 1–6. http://dx.doi.org/10.35534/fibrosis.2023.10002.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

Weiskirchen, Ralf. "Established Hepatic Stellate Cell Lines in Hepatology Research." Fibrosis 1, no. 1 (2023): 1–9. http://dx.doi.org/10.35534/fibrosis.2023.10003.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

M. Artlett, Carol, and Lianne M. Connolly. "TANGO1 Dances to Export of Procollagen from the Endoplasmic Reticulum." Fibrosis 1, no. 2 (2023): 10008. http://dx.doi.org/10.35534/fibrosis.2023.10008.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

S. Espindola, Milena, David M. Habiel, Ana Lucia Coelho, et al. "Translational Studies Reveal the Divergent Effects of Simtuzumab Targeting LOXL2 in Idiopathic Pulmonary Fibrosis." Fibrosis 1, no. 2 (2023): 1–12. http://dx.doi.org/10.35534/fibrosis.2023.10007.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

Wang, Chao, Amlan Chakraborty, Deidree V. N. Somanader, et al. "The Severity of Isoproterenol-induced Myocardial Fibrosis and Related Dysfunction in Mice is Strain-dependent." Fibrosis 1, no. 2 (2023): 1–9. http://dx.doi.org/10.35534/fibrosis.2023.10006.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

Rius Rigau, Aleix, and Clara Dees. "Mechanisms of Fibroblast Activation during Fibrotic Tissue Remodeling." Fibrosis 2, no. 1 (2024): 10002. http://dx.doi.org/10.35534/fibrosis.2024.10002.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

Lamas, Santiago, Katalin Susztak, and Fernando Rodr韌uez-Pascual. "The Cellular and Metabolic Bases of Organ Fibrosis: UNIA Workshop 2023 in Baeza, Spain." Fibrosis 2, no. 1 (2024): 10001. http://dx.doi.org/10.35534/fibrosis.2024.10001.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

Weiskirchen, Ralf, and Amedeo Lonardo. "Hepatic Stellate Cell Phenotypes in Metabolic Dysfunction-Associated Steatohepatitis (MASH)." Fibrosis 3, no. 2 (2025): 10005. https://doi.org/10.70322/fibrosis.2025.10005.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

M. Sofroniou, Michael, та Christopher A. Lemmon. "Mechanics and Synergistic Signaling of Fibronectin, Integrins, and TGF-β Isoforms". Fibrosis 3, № 1 (2025): 10003–4. https://doi.org/10.70322/fibrosis.2025.10003.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

Liu, Hongli, Huachun Cui, and Gang Liu. "The Intersection between Immune System and Idiopathic Pulmonary Fibrosis—A Concise Review." Fibrosis 3, no. 1 (2025): 10004. https://doi.org/10.70322/fibrosis.2025.10004.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

M. McFalls, Caya, and Carol M. Artlett. "NLRP3 Inflammasome and IL-11 in Systemic Sclerosis Pulmonary Fibroblasts." Fibrosis 3, no. 2 (2025): 10006. https://doi.org/10.70322/fibrosis.2025.10006.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

Castellani, Carson, Gregory Capelli, and Bryan S. Benn. "Time Is Lung: Inpatient Transbronchial Lung Cryobiopsy Decreases Wait Time to Treatment Initiation for Newly Diagnosed Interstitial Lung Disease." Fibrosis 3, no. 2 (2025): 10007. https://doi.org/10.70322/fibrosis.2025.10007.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

Papiris, Spyros A., Panayiotis G. Vlachoyiannopoulos, Maria A. Maniati, Konstantinos X. Karakostas, Stavros H. Constantopoulos, and Haralampos H. Moutsopoulos. "Idiopathic Pulmonary Fibrosis and Pulmonary Fibrosis in Diffuse Systemic Sclerosis: Two Fibroses with Different Prognoses." Respiration 64, no. 1 (1997): 81–85. http://dx.doi.org/10.1159/000196648.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

Chaturvedi, Rachana, Tejal Shah, Amita Joshi, Toshi Mishra, Manjusha Karegar, and Akash Shukla. "Histopathological Study of Non-Cirrhotic Portal Fibrosis (NCPF) With Special Emphasis on Advanced Fibrosis." Annals of Pathology and Laboratory Medicine 2, no. 12 (2018): A1002–1008. http://dx.doi.org/10.21276/apalm.2358.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

Prakash, Sadhana, Amin A. Nanji, and Phillips W. Robbins. "Fibrosin: A Novel Lymphokine in Alcohol-Induced Fibrosis." Experimental and Molecular Pathology 67, no. 1 (1999): 40–49. http://dx.doi.org/10.1006/exmp.1999.2274.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

47

Brett, Allan S., and Elizabeth H. Mack. "Fibrosing Colonpathy in Adults with Cystic Fibrosis." American Journal of Roentgenology 190, no. 1 (2008): W73. http://dx.doi.org/10.2214/ajr.06.1589.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

Schwarzenberg, S. J., C. L. Wielinski, I. Shamieh, et al. "Cystic fibrosis–associated colitis and fibrosing colonopathy." Journal of Pediatrics 127, no. 4 (1995): 565–70. http://dx.doi.org/10.1016/s0022-3476(95)70113-3.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

49

Littlewood, J. M. "Fibrosing colonopathy in children with cystic fibrosis." Postgraduate Medical Journal 72, no. 845 (1996): 129–30. http://dx.doi.org/10.1136/pgmj.72.845.129.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

50

Reichard, Kirk W., Charles D. Vinocur, Maria Franco, et al. "Fibrosing colonopathy in children with cystic fibrosis." Journal of Pediatric Surgery 32, no. 2 (1997): 237–42. http://dx.doi.org/10.1016/s0022-3468(97)90186-x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!